Ann: US patent issued for DEP cabazitaxel nanoparticle, page-14

As others have observed "Why is this significant enough to issue a notice?"

One reason might have been the desire to issue something, but I doubt this, they haven't previously been worried about silence.

Another might be that negotiations have advanced and that a potential buyer wants a clear patent for DEP Cabazitaxel with an attractive end date before stumping up cash. I thought this more likely given that SPL does have broad DEP protection through a number of patents.

Metastatic prostate cancer is currently incurable.

Sale of the patent for a specific DEP product would be an obvious outcome of a deal.